(Q35034306)

English

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

phase II clinical trial

0 references

anti-retroviral agent

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

Diana M Gibb

7

0 references

Ann Sarah Walker

17

object named as

A Sarah Walker

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Guido Castelli-Gattinara

1 reference

ORCID Public Data File 2021

13

object named as

Lynne Mofenson

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Babiker M A Abdel-Banat

2

object named as

Abdel Babiker

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gareth Tudor-Williams

16

object named as

Gareth Tudor-Williams

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Carlo Giaquinto

6

object named as

Carlo Giaquinto

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Alexandra Compagnucci

4

object named as

Alexandra Compagnucci

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

8

object named as

Lynda Harper

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

5

object named as

Susan Fiscus

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

PENPACT-1 (PENTA 9/PACTG 390) Study Team

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Hannah Castro nee Green

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Linda Harrison

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michael Hughes

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ross McKinney

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ann Melvin

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Yacine Saidi

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

M Elizabeth Smith

15

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

31 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

273-283

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Update of the drug resistance mutations in HIV-1: December 2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

A trial of three antiretroviral regimens in HIV-1-infected children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

8 July 2018

HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111069

25 October 2018

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21288774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children

1 reference

https://pubmed.ncbi.nlm.nih.gov/21288774

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CP

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970313-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral treatment for children with peripartum nevirapine exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970313-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970313-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(10)70313-3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35034306&oldid=1985631214"